DRG epidemiologists estimate that 60% of epilepsy patients experience partial-onset seizures (POS), which aretypically the gateway indication for new antiepileptic drugs (AEDs). The most frequently…
Attention-deficit/hyperactivity disorder (ADHD) is a common childhood condition that can continue through adolescence and into adulthood. Treatment options include a mix of stimulants (e.g.,…
DRG Epidemiology’s coverage of neuroendocrine tumor comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence of…
DRG Epidemiology’s coverage of neuroendocrine tumor comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence of…
DRG Epidemiology’s coverage of neuroendocrine tumor comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence of…
DRG Epidemiology’s coverage of neuroendocrine tumor comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence of…
DRG Epidemiology’s coverage of neuroendocrine tumor comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence of…
DRG Epidemiology’s coverage of neuroendocrine tumor comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence of…
MARKET OUTLOOKGrowth hormone is an endogenous hormone produced by the pituitary gland; a deficiency in its production or activity is characterized by short stature, decreased capacity for exercise…
Gastroesophageal reflux disease (GERD) is arguably the most common chronic gastrointestinal disorder, characterized by symptoms of heartburn and regurgitation. The primary objectives of GERD…
The premium-priced therapies used to treat ovarian cancer, such as Avastin (Roche/Genentech) and the PARP inhibitors Lynparza (AstraZeneca/Merck & Co), Rubraca (Clovis Oncology), and Zejula (…